<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295567</url>
  </required_header>
  <id_info>
    <org_study_id>dipy-cabg</org_study_id>
    <secondary_id>2009-014299-22</secondary_id>
    <nct_id>NCT01295567</nct_id>
  </id_info>
  <brief_title>Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?</brief_title>
  <official_title>Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective CABG?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      Due to western lifestyle human coronary arteries are prone to develop atherosclerotic&#xD;
      plaques. Hence the heart is an important target organ for atherothrombotic complications:&#xD;
      myocardial ischemia, arrhythmias, myocardial infarction and heart failure. To alleviate&#xD;
      symptoms and decrease mortality in these patients, myocardial revascularisation is&#xD;
      recommended. Coronary artery bypass grafting (CABG) is indicated in patients with severe&#xD;
      atherosclerotic disease of all three coronary arteries or the left main stem coronary artery.&#xD;
      Cardiac ischemia and reperfusion injury during CABG is inevitable and jointly accountable for&#xD;
      complications that occur after CABG (e.g. death, myocardial infarction, arrhythmias, stroke,&#xD;
      or renal complications). Dipyridamole has been shown to reduce ischemia reperfusion injury in&#xD;
      healthy volunteers using an intermediate endpoint and may prevent cardiovascular death or&#xD;
      event in secondary prevention after cerebrovascular disease. The investigators hypothesise&#xD;
      that oral pre-treatment with dipyridamole can increase cardiac tissue tolerance against&#xD;
      ischemia and reperfusion injury due to CABG. The investigators expect lower troponin-I&#xD;
      release in patients who were pretreated with dipyridamole.&#xD;
&#xD;
      Objective: To study the effect of oral pretreatment with dipyridamole on high sensitivity&#xD;
      (HS)-troponin-I release after CABG. Secondary objectives are whether oral pretreatment with&#xD;
      dipyridamole reduces postoperative CABG arrhythmias, prolonged inotropic support, and&#xD;
      duration of Intensive Care-stay. Further secondary endpoints are the effects of dipyridamole&#xD;
      pretreatment on renal injury and post-ischemic recovery of contractile function (measured&#xD;
      ex-vivo).&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The investigators hypothesize that oral pre-treatment with dipyridamole can increase cardiac&#xD;
      tissue tolerance against ischemia and reperfusion injury. The investigators expect lower&#xD;
      HS-troponin-I release in patients who were pretreated with dipyridamole. Additionally the&#xD;
      investigators expect the incidence of arrhythmias, need for prolonged inotropic support&#xD;
      (longer than 24 hours postoperative) to be decreased in pretreated patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HS-troponin-I</measure>
    <time_frame>within 72 hours after CABG.</time_frame>
    <description>high sensitivity cardiac troponin-I</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of inotropic support</measure>
    <time_frame>within three days after CABG</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of IC stay</measure>
    <time_frame>within three days after CABG</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drain production</measure>
    <time_frame>24 hours after surgery and total drain production within three days after surgery</time_frame>
    <description>thoracic drain production after CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-ischemic recovery of contractile function</measure>
    <time_frame>until 4 hours after harvesting</time_frame>
    <description>The right atrial appendage is harvested during cardiac surgery before the introduction of the extracorporal circulation. Two atrial trabeculae are dissected, suspended in an organ bath, and linked to a force transducer. after equilibration and baseline measurement, simulated ischemia and reperfusion influences contractile force recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal damage</measure>
    <time_frame>Within three days after CABG</time_frame>
    <description>biomarkers for renal failure will be detemined in blood and urine before and after CABG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dipyridamole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole</intervention_name>
    <description>prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily</description>
    <arm_group_label>dipyridamole</arm_group_label>
    <other_name>persantin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>prior to CABG surgery 3 day treatment with placebo capsules twice daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acceptation for CABG in RUNMC&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to inclusion&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Use of insulin&#xD;
&#xD;
          -  Use of sulfonylurea derivates (e.g. glibenclamide, tolbutamide, gliclazide,&#xD;
             glimepiride)&#xD;
&#xD;
          -  Use of metformin&#xD;
&#xD;
          -  Use of oral corticosteroids&#xD;
&#xD;
          -  Use of dipyridamole&#xD;
&#xD;
          -  Use of clopidogrel within 8 days prior to scheduled CABG surgery&#xD;
&#xD;
          -  Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAIDs)&#xD;
&#xD;
          -  Off-pump surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RUNMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>G. Rongen</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>ischemia reperfusion injury</keyword>
  <keyword>CABG</keyword>
  <keyword>dipyridamole</keyword>
  <keyword>HS-troponin-I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

